Molecularly matched therapies identified by comprehensive genomic profiling before the first-line setting to provide alternative treatment outcomes in patients with solid tumors: 1-year follow-up of the prospective FIRST-Dx study.

作者
Ryuji Hayashi,Junichi Matsubara,Kumi Mukai,Masahiro Yoshioka,Hidenori Kage,Katsutoshi Oda,Sadakatsu Ikeda,Hiromichi Ebi,Kei Muro,Shinya Kajiura,Reiko Ashida,Masayuki Kitano,Manabu Muto
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 3137-3137 被引量:1
标识
DOI:10.1200/jco.2024.42.16_suppl.3137
摘要

3137 Background: Comprehensive genomic profiling (CGP) test by next-generation sequencing has been reimbursed in Japan since 2019. However, only 9.4% of patients (pts) had received molecularly-matched treatment because CGP test in Japan is only indicated after standard of care (SoC). To determine the clinical utility of a CGP test (FoundationOne CDx) in the first-line setting for pts with advanced solid tumors, we previously reported the results of the FIRST-Dx study, in which the molecular tumor board identified molecular-based recommended therapy (MBRT) for 61% of pts (105/172) (Matsubara J, et al. JAMA Netw Open 2023). In this 1-year follow-up of the FIRST-Dx study, we investigated the clinical benefits provided by the upfront CGP test. Methods: The FIRST-Dx study was a multi-institutional, prospective study in 6 hospitals in Japan. Chemotherapy-naïve adult pts with advanced solid tumor (GI, Lung, Breast, GYN, Melanoma) and ECOG performance status of 0-1 were enrolled. This follow-up study was planned for 3 years and an interim analysis was prespecified at 1 year after the final patient enrollment in the FIRST-Dx study. Primary endpoint was overall survival (OS). Secondary endpoints were the proportion of pts who received MBRT, overall response rate, progression-free survival (PFS), and a PFS ratio (PFS on MBRT/PFS on prior therapy). Results: Data from 172 pts with a median follow-up of 15.1 months were available. Median OS was not reached (95% CI: 18.4 months to not reached). Thirty-nine pts (22.7%) had received MBRT. The total number of pts treated with MBRT were 21 in 1st-line, 20 in 2nd-line, 4 in 3rd-line, and 1 in 4th-line, respectively. Overall response rate was 56.3% [95% CI: 29.9-80.2%] in 1st-line MBRT group vs 42.3% [95% CI: 33.9-51.1%] in 1st-line SoC (N=137), and 26.3% [95% CI: 9.1-51.2%] in 2nd-line MBRT group vs 17.1% [95% CI: 9.7-27.0%] in 2nd-line SoC (N=82), respectively. Median PFS was 12.9 months [95% CI: 7.4 months to not reached] in 1st-line MBRT group vs 11.3 months [95% CI: 8.6-14.1 months] in 1st-line SoC, and 6.9 months [95% CI: 2.8 months to not reached] in 2nd-line MBRT group vs 5.7 months [95% CI: 3.7-7.4 months] in 2nd-line SoC, respectively. Regarding the PFS ratio of 2nd-line MBRT (N=15) (PFS on MBRT in 2nd-line/PFS on 1st-line therapy), median PFS ratio was 1.0 (range: 0.1-14.6) and 4 pts (27%) had the PFS ratio of >1.3, indicating that MBRT might be effective in changing the clinical outcome (Von Hoff DD, et al. J Clin Oncol 2010). Conclusions: We showed that MBRT identified by CGP test before the first-line setting provides better treatment outcomes than SoC in pts with solid tumors early in their disease course. Our data suggested that the timing of CGP test in Japan for pts with advanced solid tumors should be indicated before starting SoC. Clinical trial information: jRCT1050220041 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
小二郎的应助被嗷嗷ao采纳,获得10
1秒前
欧阳峰发布了新的文献求助10
1秒前
宋宋完成签到 ,获得积分10
3秒前
3秒前
4秒前
水煮电吹风的应助被剪刀手采纳,获得10
4秒前
大碗完成签到,获得积分10
5秒前
6秒前
CAOHOU的应助被吱吱采纳,获得10
6秒前
欧阳峰完成签到,获得积分10
6秒前
7秒前
7秒前
1618完成签到 ,获得积分10
7秒前
Ning_完成签到,获得积分10
7秒前
一只鱼完成签到 ,获得积分10
7秒前
8秒前
zivi完成签到,获得积分20
8秒前
易宋发布了新的文献求助10
8秒前
Owen的应助被惠1采纳,获得10
8秒前
meimei完成签到 ,获得积分10
9秒前
和道一文字完成签到,获得积分10
10秒前
kiiso发布了新的文献求助10
12秒前
12秒前
江枫渔火完成签到 ,获得积分0
13秒前
tang发布了新的文献求助10
13秒前
Juvenilesy的应助被墨尘采纳,获得10
13秒前
pmh完成签到,获得积分10
15秒前
和谐完成签到 ,获得积分10
15秒前
D_DAY完成签到,获得积分10
16秒前
17秒前
17秒前
17秒前
hudirudi完成签到,获得积分10
19秒前
神经蛙完成签到,获得积分10
19秒前
学术小白完成签到,获得积分10
19秒前
20秒前
kiterunner发布了新的文献求助10
21秒前
Hao完成签到 ,获得积分10
21秒前
misong完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621